이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Fusion Pharmaceuticals 배당금

배당금 기준 확인 0/6

Fusion Pharmaceuticals 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

n/a

지급 비율

업계 평균 수익률	1.9%
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
주당 순이익	-US$1.23
배당 수익률 예측	n/a

최근 배당금 업데이트

업데이트 없음

Recent updates

Fusion Pharmaceuticals' Partnerships Strengthen Long-Term Outlook

Mar 03

Health Check: How Prudently Does Fusion Pharmaceuticals (NASDAQ:FUSN) Use Debt?

Jan 30

Fusion Pharmaceuticals initiated at buy at Truist on lead candidate for solid tumors

Sep 16

Fusion Pharma doses first patient in phase 1/2 study for solid tumors treatment

Aug 29

Will Fusion Pharmaceuticals (NASDAQ:FUSN) Spend Its Cash Wisely?

Aug 10

Fusion Pharmaceuticals GAAP EPS of -$0.44 beats by $0.09, revenue of $0.57M beats by $0.46M

Aug 09

Fusion Pharma wins FDA nod to start trials for solid tumor candidate

Jun 23

We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate

Jan 16

We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate

Aug 28

Fusion Pharma trades higher on early-stage data for cancer therapy

Jun 14

We're Hopeful That Fusion Pharmaceuticals (NASDAQ:FUSN) Will Use Its Cash Wisely

Apr 05

How Much Of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Do Institutions Own?

Mar 01

Who Has Been Buying Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Shares?

Jan 25

Here's Why We're Not Too Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Situation

Dec 21

Fusion Pharmaceuticals EPS misses by $0.04

Nov 10

Fusion Pharma teams up with AstraZeneca in next-gen radiopharmaceuticals for cancer

Nov 02

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 FUSN 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: FUSN 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

Fusion Pharmaceuticals 시장 대비 배당 수익률

FUSN 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (FUSN)	n/a
시장 하위 25% (US)	1.4%
시장 상위 25% (US)	4.3%
업계 평균 (Biotechs)	1.9%
애널리스트 예측 (FUSN) (최대 3년)	n/a

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 FUSN 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 FUSN 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 FUSN 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: FUSN 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

Fusion Pharmaceuticals 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Recent updates

Fusion Pharmaceuticals Files Form 15

Fusion Pharmaceuticals Inc.(NasdaqGS:FUSN) dropped from NASDAQ Biotechnology Index

Fusion Pharmaceuticals Inc. Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer

First quarter 2024 earnings released: US$0.40 loss per share (vs US$0.45 loss in 1Q 2023)

Third quarter 2023 earnings released: US$0.25 loss per share (vs US$0.55 loss in 3Q 2022)

AstraZeneca AB entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN) for $1.8 billion.

Consensus EPS estimates fall by 11%

AstraZeneca AB entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN) for $1.8 billion.

AstraZeneca AB entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN) for $1.8 billion.

AstraZeneca PLC (LSE:AZN) entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN) for $1.5 billion.

Price target increased by 34% to US$18.80

AstraZeneca PLC (LSE:AZN) entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN) for $1.5 billion.

Fusion Pharmaceuticals' Partnerships Strengthen Long-Term Outlook

Health Check: How Prudently Does Fusion Pharmaceuticals (NASDAQ:FUSN) Use Debt?

Price target increased by 7.5% to US$14.27

Consensus revenue estimates increase by 266%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Fusion Pharmaceuticals Inc. Announces Board Changes

Fusion Pharmaceuticals Inc. Announces Presentation of Preclinical Data Supporting FPI-2068, A Novel Targeted Alpha Therapy for EGFR-cMET Expressing Cancers

Consensus revenue estimates increase by 160%

New minor risk - Share price stability

Consensus revenue estimates increase by 304%

Consensus revenue estimates fall by 91%

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Fusion Pharmaceuticals Inc. to Present Interim Data from Phase 1 Trial of FPI-1434 in Patients with Solid Tumors Expressing IGF-1R

Consensus revenue estimates increase by 289%

New major risk - Shareholder dilution

Fusion Pharmaceuticals Inc. announced that it expects to receive $20 million in funding from Federated Hermes, Inc.

Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T

Fusion Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2023

Price target decreased to US$13.95

Fusion Pharmaceuticals Appoints Dmitri Bobilev as Chief Medical Officer

Fusion Pharmaceuticals initiated at buy at Truist on lead candidate for solid tumors

Fusion Pharmaceuticals Inc. Announces First Patient Dosed in Phase 1/2 Study of FPI-1966 in Patients with Advanced Solid Tumors Expressing FGFR3

Fusion Pharma doses first patient in phase 1/2 study for solid tumors treatment

Independent Director recently bought US$90k worth of stock

Will Fusion Pharmaceuticals (NASDAQ:FUSN) Spend Its Cash Wisely?

Fusion Pharmaceuticals GAAP EPS of -$0.44 beats by $0.09, revenue of $0.57M beats by $0.46M

Price target decreased to US$16.14

Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-2059, an Investigational Small Molecule-Based Radiopharmaceutical Targeting Solid Tumors Expressing NTSR1

Fusion Pharma wins FDA nod to start trials for solid tumor candidate

Fusion Pharmaceuticals Presents Imaging Data from Cold Antibody Sub-Study in the Phase 1 Study of FPI-1434

Fusion Pharmaceuticals Inc. Provides Updates on FPI-1434 and FPI-1966 Clinical Programs

Consensus revenue estimates fall by 84%

Fusion Pharmaceuticals Inc. Announces Executive Changes

Price target decreased to US$18.20

We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate

Fusion Pharmaceuticals Announces Nomination of First Targeted Alpha Therapy Candidate in Collaboration with AstraZeneca to Advance into IND-Enabling Studies for Phase 1 Development

Price target decreased to US$19.00

We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate

Price target decreased to US$21.33

Consensus revenue estimates fall to US$173.7k

Fusion Pharmaceuticals Announces Preliminary Safety and Dosimetry Results from its Single-Dose Portion of the Phase 1 Study of FPI-1434

Fusion Pharma trades higher on early-stage data for cancer therapy

Consensus forecasts updated

We're Hopeful That Fusion Pharmaceuticals (NASDAQ:FUSN) Will Use Its Cash Wisely

New 90-day low: US$11.25

How Much Of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Do Institutions Own?

Fusion Pharmaceuticals Appoints Philina Lee to Its Board of Directors

New 90-day low: US$11.26

Who Has Been Buying Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Shares?

New 90-day low: US$11.56

Here's Why We're Not Too Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Situation

TRIUMF Enters Collaboration with Fusion Pharmaceuticals to Boost Production of Actinium-225, A Cancer-Fighting Medical Isotope

Fusion Pharmaceuticals Inc. Initiates Multi-Dose Portion of Phase 1 Trial of FPI-1434 in Patients with Advanced Solid Tumors

Fusion Pharmaceuticals EPS misses by $0.04

New 90-day high: US$13.73

Fusion Pharmaceuticals Inc. Appoints Barbara Duncan as Chairperson of the Board of Directors

Fusion Pharma teams up with AstraZeneca in next-gen radiopharmaceuticals for cancer

Fusion Pharmaceuticals Appoints Maria Stahl as Chief Legal Officer

New 90-day low: US$12.20

결제의 안정성과 성장

시장 대비 배당 수익률

주주에 대한 수익 배당금

주주에 대한 현금 배당금